Table 3 Classification of 48 validation set patients into risk groups based on the commercial and RUO RS.

From: Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Commercial RS (RT-PCR)

RUO RS (NanoString-derived)

Low

Intermediate

High

Total

Low

24

3

0

27

Intermediate

2

7

1

10

High

0

0

11

11

Total

26

10

12

48

Back to article page